Inventor · disambiguated record
Thomas M. Cardillo
Also filed as: CARDILLO THOMAS M
9 granted patents·3 pending applications·71 citations·filing 2016–2021
87Inventor score
Top patents by PatentIndex Score
12 records- 0197US10195175B2Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitorsIMMUNOMEDICS INC·Filed 2017·Granted Feb 5, 2019·18 cites·12 claims
- 0297US9707302B2Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancerIMMUNOMEDICS INC·Filed 2016·Granted Jul 18, 2017·23 cites·19 claims
- 0395US10206918B2Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancersIMMUNOMEDICS INC·Filed 2017·Granted Feb 19, 2019·10 cites·23 claims
- 0494US11439620B2Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitorsIMMUNOMEDICS INC·Filed 2018·Granted Sep 13, 2022·6 cites·13 claims
- 0594US10058621B2Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancersIMMUNOMEDICS INC·Filed 2017·Granted Aug 28, 2018·7 cites·23 claims
- 0691US10918734B2Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51IMMUNOMEDICS INC·Filed 2018·Granted Feb 16, 2021·5 cites·23 claims
- 0788US10709701B2Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancersIMMUNOMEDICS INC·Filed 2018·Granted Jul 14, 2020·2 cites·24 claims
- 0868US10988539B2Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancersIMMUNOMEDICS INC·Filed 2018·Granted Apr 27, 2021·0 cites·14 claims
- 0963US11253606B2Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancerIMMUNOMEDICS INC·Filed 2019·Granted Feb 22, 2022·0 cites·20 claims
- 1052US2017274093A1Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancerIMMUNOMEDICS INC·Filed 2017·Application pending·0 cites
- 1152US2021316003A1Biomarkers for sacituzumab govitecan therapyCARDILLO THOMAS M·Filed 2021·Application pending·0 cites
- 1252US2021093730A1Biomarkers for antibody-drug conjugate monotherapy or combination therapyIMMUNOMEDICS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thomas M. Cardillo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →